ViiVHealthcare US

You are about to leave ViiVMedinfo.

By clicking "Allow," you will be taken to a website that is independent of ViiV Healthcare. The site you linking to is not controlled or endorsed by ViiV Healthcare, and ViiV Healthcare is not responsible for the content provided on that site.

DOVATO

Dovato

Dovato

(dolutegravir and lamivudine)

Dovato, a two-drug combination of dolutegravir (integrase strand transfer inhibitor [INSTI]) and lamivudine (nucleoside analogue reverse transcriptase inhibitor [NRTI]).

Prescribing Information, including boxed warning

Patient Information

Medical Shorts

Virologic Response in Patients with Low Baseline CD4 Cell Counts on Dovato: DOLCE Study

Clinical Trial Data Comparing Dovato or Bictegravir/Emtricitabine/Tenofovir Alafenamide

Use of Dovato in Patients With M184V/I Resistance Mutation

Use of Dovato in ‘Test and Treat’ Strategy

Virologic Response in Patients with High Baseline Viral Loads receiving Dovato

Connect with ViiV Medical Experts

Call 1-888-226-8434
Weekdays from 8 AM to 6 PM ET
(5 AM – 3 PM PT)

Find my ViiV MSL

Request a scientific discussion

Report an Adverse Event

To report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at https://gsk.public.reportum.com or 1-877-844-8872, or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch.

ViiVHealthcare US

This site is intended for US Healthcare Professionals Only. It may include information about products or uses that have not been approved by the US Food and Drug Administration.

Trademarks are owned by or licensed to the ViiV Healthcare group of companies.

©2025 ViiV Healthcare group of companies or its licensor. Produced in USA. February 2025

  • Terms of Use
  • Cookie Policy
  • Privacy Notice
  • ViiVHealthcare.com